IP Library Granted Patent US 7,968,092
Granted Patent B2
US 7,968,092 · App. 11/387,997 · Granted Jun 28, 2011

Human binding molecule against CD1a

Assignees: Crucell Holland B.V.; The Johns Hopkins University
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,968,092
App. No.
11/387,997
Granted
Jun 28, 2011
Kind
B2
Abstract

The present invention provides human binding molecules that specifically bind to CD1 a , nucleic acid molecules encoding the human binding molecules, compositions comprising the human binding molecules and methods of identifying or producing the human binding molecules. The human binding molecules can be used in the diagnosis, prevention and treatment of neoplastic disorders and diseases.

Claims (9)

1. A monoclonal antibody that binds to human CD1a, wherein the monoclonal antibody is selected from the group consisting of:

a) a monoclonal antibody that comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:8, and a light chain variable region comprising SEQ ID NO: 20; and

b) a monoclonal antibody that comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:18, and a light chain variable region comprising SEQ ID NO: 20.

2. A monoclonal antibody capable of specifically binding to human CD1a, wherein the monoclonal antibody is selected from the group consisting of:

a) a monoclonal antibody that comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:8, and a light chain variable region comprising SEQ ID NO: 20; and

b) a monoclonal antibody that comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:18, and a light chain variable region comprising SEQ ID NO: 20.

3. The monoclonal antibody of claim 1 , wherein the monoclonal antibody is an IgG1.

4. The monoclonal antibody of claim 1 , wherein the antibody has cytotoxic activity against a CD1a-expressing cell.

5. A composition comprising the monoclonal antibody of claim 1 .

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 10, 2006
From: THROSBY, MARK; VAN MEIJER, MARJA; GERMERAAD, WILFRED T.V.; KRUISBEEK, ADA M.
To: CRUCELL HOLLAND B.V.
Reel/Frame 018080/0045 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 10, 2006
From: ARCECI, ROBERT J.
To: JOHNS HOPKINS UNIVERSITY, THE
Reel/Frame 018081/0074 →
Priority Claims (2)
WO PCT/EP03/51096 · Dec 23, 2003 · international
WO PCT/EP2004/052110 · Sep 9, 2004 · international
Continuity (2)
Continuation In Part PCTEP2004053639 · Dec 21, 2004
Related Publication 20060257397A1 · Nov 16, 2006